TITLE

Sirion Therapeutics announces FDA approval of Zirgan

PUB. DATE
December 2009
SOURCE
Primary Care Optometry News;Dec2009, Vol. 14 Issue 12, p23
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
This article reports on the approval received by Sirion Therapeutics from the U.S. Food and Drug Administration on its new drug application for Zirgan for the treatment of acute herpetic keratitis.
ACCESSION #
45566963

 

Related Articles

  • Sirion Drug Approved for Herpetic Keratitis.  // Review of Ophthalmology;Oct2009, Vol. 16 Issue 10, p9 

    The article reports on the approval of the drug Zirgan from Sirion Therapeutics Inc. by the Food and Drug Administration (FDA) in the U.S. It highlights that the drug is for the treatment of herpetic keratitis or dendritic ulcer. According to the article, the FDA has granted approval for the...

  • FDA approves ophthalmic gel. Guttman, Cheryl; Kaufman, Herbert E. // Ophthalmology Times;10/15/2009, Vol. 34 Issue 20, p1 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) of ganciclovir ophthalmic gel 0.15% which is used to treat acute herpetic keratitis. The approval brings ophthalmologists a significant advancement in topical antiviral therapy for a condition which is the leading...

  • Sirion's Durezol Wins FDA Approval.  // Bioworld Week;6/30/2008, Vol. 16 Issue 26, p3 

    The article reports that Sirion Therapeutics Inc.'s Durezol has gained U.S. Food and Drug Administration approval in post-operative ocular inflammation and pain. Durezol, a difluorinated derivative of prednisolone, has been shown to rapidly reduce inflammation and pain in patients diagnosed with...

  • Strong, Yet Gentle. Bowling, Ernie; Russell, Gregg E. // Review of Optometry;Mar2010 Strategies, p8 

    The article focuses on the approval of gancyclovir ointment Zirgan from Sirion Therapeutics Inc. by the U.S. Food and Drug Administration (FDA) for the treatment of herpetic keratitis. It notes that Zirgan has been the standard for treating ocular herpes outside U.S. and its approval represents...

  • Corrections.  // Review of Ophthalmology;Dec2009, Vol. 16 Issue 12, p6 

    Corrections to articles published in the November 2009 issue are presented including the "Management of Retinal Vein Occlusion" and the U.S. Food and Drug Administration's approval to Sirion Therapeutics Inc.'s Durezol.

  • Sirion Therapeutics Launches Durezol.  // Review of Ophthalmology;Nov2008 Part 1 of 2, Vol. 15 Issue 11, p4 

    The article reports on the commercial availability of Durezol 0.05% from Sirion Therapeutics Inc. which was approved by the Food and Drug Administration in the U.S. Durezol is a topical ophthalmic corticosteroid which was approved for the treatment of inflammation and pain associated with ocular...

  • FDA Approval for Sirion Therapeutics' Durezol.  // Review of Ophthalmology;Jul2008 Part 1 of 2, Vol. 15 Issue 7, p6 

    The article reports that the U.S. Food & Drug Administration (FDA) has approved the new drug Durezol from Sirion Therapeutics Inc. The new drug is a potent topical steroid for the treatment of postoperative ocular inflammation and pain. President and chief executive officer (CEO) of Sirion...

  • Industry News in Brief. Master, Joseph; Vasta, Stephanie // Ocular Surgery News;4/10/2008, Vol. 26 Issue 7, p12 

    This section offers news briefs relevant to the ophthalmological industry. Visian Toric Implantable Collamer Lens from STAAR Surgical was approved by the Chinese government. Sirion Therapeutics has applied for the U.S. Food and Drug Administration (FDA) drug approval for its brand of...

  • Regulatory Roundup.  // BioWorld Today;3/17/2009, Vol. 20 Issue 50, p4 

    The article reports on an announcement by Sirion Therapeutics Inc. that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental new drug application (NDA) for Durezol 0.05 percent to treat endogenous anterior uveitis. The drug was approved by the FDA in June 2008 for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics